Report cover image

Global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Insights, Forecast to 2028

Publisher QYResearch Group
Published Apr 01, 2022
Length 110 Pages
SKU # QYR17154104

Description

Global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Insights, Forecast to 2028

Market Analysis and Insights: Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market

This report focuses on global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies market.
In 2021, the global T-Cell & NK-Cell Engaging Bispecific Antibodies market size was US$ 472 million and it is expected to reach US$ 5072 million by the end of 2028, with a CAGR of 40.82% during 2021-2028. In Japan the T-Cell & NK-Cell Engaging Bispecific Antibodies market size is expected to grow from US$ 1.88 million in 2021 to US$ 173.15 million by 2028, at a CAGR of 99.82% during the forecast period.
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Scope and Market Size
T-Cell & NK-Cell Engaging Bispecific Antibodies market is segmented by players, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global T-Cell & NK-Cell Engaging Bispecific Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and By Application in terms of revenue and forecast for the period 2017-2028.

By Company

Amgen
Immunocore
Johnson & Johnson
Roche
Company Five
AbbVie
MacroGenics
Regeneron
Astellas Pharma
GEMoaB Monoclonals
Molecular Partners
AstraZeneca
Merck
Eli Lilly
IGM Biosciences
Novartis
CytomX Therapeutics
Lava Therapeutics
Takeda

Segment by Type

T Cell Engagers
NK Cell Engagers

Segment by Application

Hematological Cancers
Solid Tumors

By Region

North America
United States
Canada
Mexico

Asia-Pacific
China
Japan
South Korea
Southeast Asia
Australia
India
Rest of Asia

Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe

South America
Brazil
Rest of South America

Middle East & Africa
Middle East
Africa

Table of Contents

110 Pages
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 T Cell Engagers
1.2.3 NK Cell Engagers
1.3 Market by Application
1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hematological Cancers
1.3.3 Solid Tumors
1.4 Study Objectives
1.5 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Perspective (2017-2028)
2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Trends by Regions
2.2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions: 2017 VS 2021 VS 2028
2.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Regions (2017-2022)
2.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028)
2.2.4 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028
2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Dynamic
2.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
2.3.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
2.3.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
2.3.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue
3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue (2017-2022)
3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Players (2017-2022)
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue
3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio
3.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 2 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021
3.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Players Head office and Area Served
3.6 Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
3.7 Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY TYPE
4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Type (2017-2022)
4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028)
5 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY APPLICATION
5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Application (2017-2022)
5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028)
6 NORTH AMERICA
6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
6.4 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
7 EUROPE
7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
7.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 ASIA-PACIFIC
8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
8.3 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
8.4 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
9 SOUTH AMERICA
9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
9.3 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
9.4 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
9.4.1 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
10.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
10.4 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
10.4.1 Middle East
10.4.2 Africa
11 KEY PLAYERS PROFILES
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.1.4 Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
11.1.5 Amgen Recent Development
11.2 Immunocore
11.2.1 Immunocore Company Details
11.2.2 Immunocore Business Overview
11.2.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.2.4 Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
11.2.5 Immunocore Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.3.4 Johnson & Johnson Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.4.4 Roche Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.5.4 Pfizer Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.6.4 AbbVie Recent Development
11.7 MacroGenics
11.7.1 MacroGenics Company Details
11.7.2 MacroGenics Business Overview
11.7.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.7.4 MacroGenics Recent Development
11.8 Regeneron
11.8.1 Regeneron Company Details
11.8.2 Regeneron Business Overview
11.8.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
11.8.4 Regeneron Recent Development
11.9 Astellas Pharma
11.9.1 Astellas Pharma Company Details
11.9.2 Astellas Pharma Business Overview
11.9.3 Astellas Pharma Recent Development
11.10 GEMoaB Monoclonals
11.10.1 GEMoaB Monoclonals Company Details
11.10.2 GEMoaB Monoclonals Business Overview
11.10.3 GEMoaB Monoclonals Recent Development
11.11 Molecular Partners
11.11.1 Molecular Partners Company Details
11.11.2 Molecular Partners Business Overview
11.11.3 Molecular Partners Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Recent Development
11.13 Merck
11.13.1 Merck Company Details
11.13.2 Merck Business Overview
11.13.3 Merck Recent Development
11.14 Eli Lilly
11.14.1 Eli Lilly Company Details
11.14.2 Eli Lilly Business Overview
11.14.3 Eli Lilly Recent Development
11.15 IGM Biosciences
11.15.1 IGM Biosciences Company Details
11.15.2 IGM Biosciences Business Overview
11.15.3 IGM Biosciences Recent Development
11.16 Novartis
11.16.1 Novartis Company Details
11.16.2 Novartis Business Overview
11.16.3 Novartis Recent Development
11.17 CytomX Therapeutics
11.17.1 CytomX Therapeutics Company Details
11.17.2 CytomX Therapeutics Business Overview
11.17.3 CytomX Therapeutics Recent Development
11.18 Lava Therapeutics
11.18.1 Lava Therapeutics Company Details
11.18.2 Lava Therapeutics Business Overview
11.18.3 Lava Therapeutics Recent Development
11.19 Takeda
11.19.1 Takeda Company Details
11.19.2 Takeda Business Overview
11.19.3 Takeda Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (US$ Million): 2017 VS 2021 VS 2028
Table 4. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (2017-2022) & (US$ Million)
Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2017-2022)
Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028) & (US$ Million)
Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2023-2028)
Table 8. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
Table 9. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
Table 10. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
Table 11. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Players (2017-2022) & (US$ Million)
Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Players (2017-2022)
Table 14. Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies as of 2022)
Table 15. Ranking of Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Companies by Revenue (US$ Million) in 2021
Table 16. Global 5 Largest Players Market Share by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (CR5 and HHI) & (2017-2022)
Table 17. Key Players Headquarters and Area Served
Table 18. Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
Table 19. Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
Table 20. Mergers & Acquisitions, Expansion Plans

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us